Management of Treatment-Refractory UTI in CKD

Immediate Diagnostic Steps

• The American Urological Association suggests that upper tract imaging (CT or ultrasound) and repeat urine culture from a freshly placed catheter should be obtained immediately for patients with treatment-refractory UTI, with suspected carbapenem-resistant Enterobacterales (CRE) 1, 2
• The Infectious Diseases Society of America recommends considering carbapenem-resistant organisms (CRE or metallo-β-lactamase producers) or unrecognized upper tract complications (abscess, stones, obstruction) in patients who fail to respond to meropenem, tigecycline, and levofloxacin 1, 2, 3
• Inadequate source control (infected catheter, obstruction) should also be considered in patients with treatment-refractory UTI 3, 4

Critical Imaging Requirements

• The American College of Radiology recommends ordering upper tract imaging immediately (CT preferred over ultrasound) to evaluate for renal or perinephric abscess, obstructing stones or hydronephrosis, and emphysematous pyelonephritis in patients with febrile UTI who fail to respond to appropriate antibiotics 3

Culture Optimization

• The Clinical and Laboratory Standards Institute recommends replacing any indwelling catheter that has been in place ≥2 weeks before obtaining culture, and obtaining urine specimen from the freshly placed catheter after allowing accumulation while plugging it 3, 4, 5
• The Infectious Diseases Society of America suggests requesting extended susceptibility testing including newer β-lactam/β-lactamase inhibitor combinations for patients with treatment-refractory UTI 1, 2

Antibiotic Escalation Strategy

• The Infectious Diseases Society of America recommends using ceftazidime-avibactam 2.5g IV q8h or meropenem-vaborbactam 4g IV q8h for severe infections with suspected CRE, with dose adjustment for CKD 1, 2
• The European Society of Clinical Microbiology and Infectious Diseases suggests using aztreonam 2g IV q8h plus ceftazidime-avibactam 2.5g IV q8h (synergistic combination) for metallo-β-lactamase (MBL) producers 1, 2

Critical Pitfalls to Avoid

• The National Kidney Foundation recommends avoiding nitrofurantoin, tetracyclines, and prolonged aminoglycoside courses (>7 days) in patients with CKD due to nephrotoxicity concerns 2, 6
• The American Society of Nephrology suggests using tigecycline with caution in patients with CKD, considering high-dose regimen (100mg loading, then 50mg q12h) 1, 2

Source Control Imperatives

• The American Urological Association recommends surgical/urological intervention for patients with treatment-refractory UTI who have abscess requiring drainage, obstructing stone present, or infected catheter that cannot be removed 3, 4

Duration and Monitoring

• The Infectious Diseases Society of America recommends treatment duration of 7-14 days depending on clinical response and source control, and monitoring renal function every 48-72 hours given CKD and nephrotoxic antibiotic exposure 2, 4
• The European Society of Clinical Microbiology and Infectious Diseases suggests considering infectious disease consultation for multidrug-resistant organisms 1, 2

De-escalation Strategy

• The Infectious Diseases Society of America recommends narrowing to the most specific agent with renal-appropriate dosing once culture results are available, and transitioning to oral therapy only if susceptible organism identified and clinical improvement documented 1, 4, 6